CPhI release the findings the 2017 India Pharma Market Report, which identified a two-tier manufacturing market and forecast increased acquisitions by Indian companies, along with a notable improvement in the international reputation of Indian made pharmaceuticals.
But, perhaps most dramatically, a large majority of domestic companies called for urgent government support to invest in API sites.
The report, which consolidated opinions from 500 domestic and international companies, identified four main areas Indian pharma companies are investing in – with 50% raising funds this year for “commercial scale and scale-up” — around one third for “continuous processing” and more than 20% each in both “biologics” and “aseptic/sterile.”
During the next 3 years, however, the number of companies planning to invest in biomanufacturing facilities rises to one third. It’s notable that the more expensive facilities and capabilities needed for continuous processing and biomanufacturing are being added to India’s traditional base of commercial-scale finished-product facilities.
During the next 1–3 years, 36% of Indian pharma companies are planning acquisitions, 20% are looking at facilities in the USA and Europe, with 7% exploring options in the rest of the world. Domestic acquisitions also point towards a scramble amongst many SMEs for greater size and scale, with some 25% also looking at facilities within India itself.
These findings are announced ahead of CPhI India (27-30th November, 2017), which is forecast to reach a remarkable 40,000 attendees, with overseas interest in the country growing rapidly.
The report also highlighted that the international reputation of the country on “data integrity” has also improved massively; 96% agree that the CDSCO certification programmes and initiatives are helping increase compliance. Even more impressive is the fact that 52% of international respondents believed the CDSCO is moving toward comparability with the regulatory standards of the EMA and FDA.
A major concern highlighted amongst domestic companies (86%) was an over reliance on Chinese ingredients within the finished formulations sector. In fact, the majority of domestic companies (81%) believe that the Indian government needs to “urgently invest in domestic API facilities and provide tax-breaks and incentives to secure the Indian generics industry” and prevent losses in market share.
Chief amongst the growth drivers reported are strong domestic sales in the next 2–3 years, generic APIs exports, as well as finished formulation for developed markets. Finally, 41% of international respondents believed that more biologic alliances – similar to the Mylan-Bocon partnership – may develop between India and the West in the future, with 30% believing these will proliferate in the next 3–5 years.
One interesting perspective on the India finished dosage sector – well known as the world’s leading exporter – is the identification of a two-tier system, with business models targeting different types of foreign market.
The first type is targeting predominately the Western pharma economies, consisting mainly of the United States and Europe. In this market, India is a prime provider of complex generics, branded drugs/OTC and biosimilars owing to its cost-efficient and high quality products.
Larger pharma companies are now looking beyond these two Western markets and expanding into Japan, as generic use is forecast to expand rapidly – after many years of largely on-patent drugs – yielding greater profit opportunities.
By contrast, India’s smaller and medium sized pharma companies (type 2) have focused on developing countries as their export market; in particular, on high-volume, low-margin generic products.
Consolidation amongst these providers is highly likely as they try and progress-up the value chain, and move into formulations with greater margins – companies also require a certain size and financial flexibility to invest in the newer types of products coming into the market.
Finally, the report argued the biosimilars and biologic sector is now the hotbed of national innovation, and will see well above-market growth in India. With more biologics coming off-patent in the near future, there is a growing opportunity for pharma companies to make increased profits via biosimilars with interchangeable standards.
Rutger Oudejans, Brand Director, Pharma, UBM EMEA, notes: “CPhI India has seen dramatic changes in the last couple of years as increasingly all of world pharma is attending and domestic companies are investing in new types of manufacturing equipment and even biologics.”
“It is an extremely dynamic market with standards and its global reputation catching-up with the on-the-ground realities. This year, we anticipate an enormous 40,000 attendees and we expect the number of multinationals and new innovations emerging out of the country to accelerate. Frankly, we were taken aback by the overwhelming positivity of our report’s findings, with only supply chain ingredient concerns identified as a potential drag on growth.”